Kilitch Drugs (India) Limited
KILITCH · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹247.35.
Piotroski F-score 1/9 — quality of earnings & balance sheet.
Investability checklist
- ✕ROE above 15%12.4%
- ✓Low debt (D/E < 0.5)0.32x
- ✕Positive free cash flow
- ✓Revenue growth > 10%46%
- ✓Earnings growing27%
- ✓Net margin ≥ 10%12.8%
- ✓Current ratio > 1.51.83
- ✓Below our fair value
- ✓Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- –Altman Z in safe zone
- ✕Piotroski ≥ 71/9
1-year price
EOD · 2026-06-16Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
Weaknesses
- •Weak Piotroski score (1/9).
Opportunities
- •Earnings growing (27% YoY).
- •Revenue growing (46% YoY).
- •Trading in our value buy zone versus sector peers.
- •Trades ~67% below our estimated fair value.
About Kilitch Drugs (India) Limited
Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally. The company offers various parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops for gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.